[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616006":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":23,"locations":30,"responsibleParty":133,"collaborators":10,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":10,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":10,"enrollmentInfo":144,"targetDuration":10,"studyType":147,"phases":10,"briefSummary":148,"conditions":149,"keywords":155,"overallStatus":160,"whyStopped":10,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Sigmund Freud PrivatUniversitat","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"IVT group",null,"Patients who received intravenous thrombolysis as part of acute stroke treatment, if eligible.",{"label":13,"type":10,"description":14,"interventionNames":10},"Antiplatelet group","Patients who received SAPT or DAPT as part of acute stroke treatment.",[16,20],{"name":17,"affiliation":18,"role":19},"Julian Frederic Hotz, DDr.","1. Department of Neurology, St. John's Hospital, Vienna, Austria, 2. Department of Neurology, University Hospital, Bern, Switzerland, 3. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":22,"role":19},"Marek Sykora, Prof. Dr.","1. Sigmund Freud University Vienna, Austria, 2. Department of Neurology, St. John's Hospital, Vienna, Austria",[24,28],{"name":17,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+43 1 211210","julian.hotz@meduniwien.ac.at",{"name":21,"role":25,"phone":26,"phoneExt":10,"email":29},"marek.sykora@bbwien.at",[31,46,57,73,87,101,116],{"facility":32,"status":10,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Department of Neurology, St. John's Hospital, Vienna, Austria","Vienna","1020","Austria","AT",{"type":38,"coordinates":39},"Point",[40,41],16.37208,48.20849,{"lat":41,"lon":40},[44,45],{"name":17,"role":25,"phone":26,"phoneExt":10,"email":27},{"name":21,"role":25,"phone":26,"phoneExt":10,"email":29},{"facility":47,"status":10,"city":33,"state":10,"zip":48,"country":35,"countryCode":36,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Department of Neurology, Medical University of Vienna","1090",{"type":38,"coordinates":50},[40,41],{"lat":41,"lon":40},[53],{"name":54,"role":25,"phone":55,"phoneExt":10,"email":56},"Stefan Greisenegger, Prof. Dr.","+43 1 404000","stefan.greisenegger@meduniwien.ac.at",{"facility":58,"status":10,"city":59,"state":10,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Department of Neurology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin","Berlin","12200","Germany","DE",{"type":38,"coordinates":64},[65,66],13.41053,52.52437,{"lat":66,"lon":65},[69],{"name":70,"role":25,"phone":71,"phoneExt":10,"email":72},"Christian Nolte, Prof. Dr.","+49 30 450 560 676","christian.nolte@charite.de",{"facility":74,"status":10,"city":75,"state":10,"zip":76,"country":61,"countryCode":62,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Department of Neurology, Heidelberg University Hospital","Heidelberg","69120",{"type":38,"coordinates":78},[79,80],8.69079,49.40768,{"lat":80,"lon":79},[83],{"name":84,"role":25,"phone":85,"phoneExt":10,"email":86},"Jan Purrucker, Prof. Dr.","00496221560","jan.purrucker@med.uni-heidelberg.de",{"facility":88,"status":10,"city":89,"state":10,"zip":90,"country":61,"countryCode":62,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Department of Neurology & Stroke, University of Tübingen","Tübingen","72076",{"type":38,"coordinates":92},[93,94],9.05222,48.52266,{"lat":94,"lon":93},[97],{"name":98,"role":25,"phone":99,"phoneExt":10,"email":100},"Sven Poli, Prof. Dr.","00497071290","sven.poli@uni-tuebingen.de",{"facility":102,"status":10,"city":103,"state":10,"zip":104,"country":105,"countryCode":106,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Department of Neurology, Universityhospital of Bern","Bern","3010","Switzerland","CH",{"type":38,"coordinates":108},[109,110],7.44744,46.94809,{"lat":110,"lon":109},[113],{"name":17,"role":25,"phone":114,"phoneExt":10,"email":115},"0041316320648","julian.hotz@insel.ch",{"facility":117,"status":10,"city":118,"state":10,"zip":119,"country":105,"countryCode":106,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Stroke Center, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne","Lausanne","1005",{"type":38,"coordinates":121},[122,123],6.63282,46.516,{"lat":123,"lon":122},[126,130],{"name":127,"role":25,"phone":128,"phoneExt":10,"email":129},"Patrik Michel, Prof. Dr.","+41 21 314 11 11","patrik.michel@chuv.ch",{"name":131,"role":25,"phone":128,"phoneExt":10,"email":132},"Davide Strambo, PD Dr.","davide.strambo@chuv.ch",{"type":134,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006",false,"NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.","ALL","18 Years",{"count":145,"type":146},462,"ESTIMATED","OBSERVATIONAL","Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[150,151,152,153,154],"Stroke","Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","Acute Ischemic Stroke",[156,157,151,158,159],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","NOT_YET_RECRUITING","2025-12-10",{"date":163,"type":164},"2025-12-23","ACTUAL",{"date":166,"type":146},"2026-01-01",{"date":168,"type":146},"2026-04-30",{"name":5,"class":6},7]